These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 24495352)
1. Suppression of neuroinflammation in forebrain-specific Cdk5 conditional knockout mice by PPARγ agonist improves neuronal loss and early lethality. Utreras E; Hamada R; Prochazkova M; Terse A; Takahashi S; Ohshima T; Kulkarni AB J Neuroinflammation; 2014 Feb; 11():28. PubMed ID: 24495352 [TBL] [Abstract][Full Text] [Related]
2. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. Chen J; Li S; Sun W; Li J PLoS One; 2015; 10(4):e0123864. PubMed ID: 25875370 [TBL] [Abstract][Full Text] [Related]
3. Conditional deletion of neuronal cyclin-dependent kinase 5 in developing forebrain results in microglial activation and neurodegeneration. Takahashi S; Ohshima T; Hirasawa M; Pareek TK; Bugge TH; Morozov A; Fujieda K; Brady RO; Kulkarni AB Am J Pathol; 2010 Jan; 176(1):320-9. PubMed ID: 19948833 [TBL] [Abstract][Full Text] [Related]
4. Cdk5 is required for the positioning and survival of GABAergic neurons in developing mouse striatum. Sasamoto K; Nagai J; Nakabayashi T; He X; Ohshima T Dev Neurobiol; 2017 Apr; 77(4):483-492. PubMed ID: 27480591 [TBL] [Abstract][Full Text] [Related]
5. PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress. Kono T; Ahn G; Moss DR; Gann L; Zarain-Herzberg A; Nishiki Y; Fueger PT; Ogihara T; Evans-Molina C Mol Endocrinol; 2012 Feb; 26(2):257-71. PubMed ID: 22240811 [TBL] [Abstract][Full Text] [Related]
6. Involvement of aberrant cyclin-dependent kinase 5/p25 activity in experimental traumatic brain injury. Yousuf MA; Tan C; Torres-Altoro MI; Lu FM; Plautz E; Zhang S; Takahashi M; Hernandez A; Kernie SG; Plattner F; Bibb JA J Neurochem; 2016 Jul; 138(2):317-27. PubMed ID: 26998748 [TBL] [Abstract][Full Text] [Related]
7. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation. Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559 [TBL] [Abstract][Full Text] [Related]
8. The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Zhao Y; Patzer A; Gohlke P; Herdegen T; Culman J Eur J Neurosci; 2005 Jul; 22(1):278-82. PubMed ID: 16029218 [TBL] [Abstract][Full Text] [Related]
9. Crosstalk between Cdk5/p35 and ERK1/2 signalling mediates spinal astrocyte activity via the PPARγ pathway in a rat model of chronic constriction injury. Zhong Y; Chen J; Chen J; Chen Y; Li L; Xie Y J Neurochem; 2019 Oct; 151(2):166-184. PubMed ID: 31314915 [TBL] [Abstract][Full Text] [Related]
12. Neuronal seipin knockout facilitates Aβ-induced neuroinflammation and neurotoxicity via reduction of PPARγ in hippocampus of mouse. Qian Y; Yin J; Hong J; Li G; Zhang B; Liu G; Wan Q; Chen L J Neuroinflammation; 2016 Jun; 13(1):145. PubMed ID: 27287266 [TBL] [Abstract][Full Text] [Related]
14. The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARγ-mediated alteration of microglial activation phenotypes. Zhao Q; Wu X; Yan S; Xie X; Fan Y; Zhang J; Peng C; You Z J Neuroinflammation; 2016 Oct; 13(1):259. PubMed ID: 27716270 [TBL] [Abstract][Full Text] [Related]
16. PPARgamma agonist pioglitazone reduces [corrected] neuronal cell damage after transient global cerebral ischemia through matrix metalloproteinase inhibition. Lee KJ; Jang YH; Lee H; Yoo HS; Lee SR Eur J Neurosci; 2008 Jan; 27(2):334-42. PubMed ID: 18215232 [TBL] [Abstract][Full Text] [Related]
17. Protection against alcohol-induced neuronal and cognitive damage by the PPARγ receptor agonist pioglitazone. Cippitelli A; Domi E; Ubaldi M; Douglas JC; Li HW; Demopulos G; Gaitanaris G; Roberto M; Drew PD; Kane CJM; Ciccocioppo R Brain Behav Immun; 2017 Aug; 64():320-329. PubMed ID: 28167117 [TBL] [Abstract][Full Text] [Related]
18. Forebrain-specific deletion of Cdk5 in pyramidal neurons results in mania-like behavior and cognitive impairment. Su SC; Rudenko A; Cho S; Tsai LH Neurobiol Learn Mem; 2013 Oct; 105():54-62. PubMed ID: 23850563 [TBL] [Abstract][Full Text] [Related]
19. GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain. Amato AA; Rajagopalan S; Lin JZ; Carvalho BM; Figueira AC; Lu J; Ayers SD; Mottin M; Silveira RL; Souza PC; Mourão RH; Saad MJ; Togashi M; Simeoni LA; Abdalla DS; Skaf MS; Polikparpov I; Lima MC; Galdino SL; Brennan RG; Baxter JD; Pitta IR; Webb P; Phillips KJ; Neves FA J Biol Chem; 2012 Aug; 287(33):28169-79. PubMed ID: 22584573 [TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Patzer A; Zhao Y; Stöck I; Gohlke P; Herdegen T; Culman J Eur J Neurosci; 2008 Nov; 28(9):1786-94. PubMed ID: 18973594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]